Abstract
Allergen specific immunotherapy (ASIT) has been used for 100 years with efficacy confirmed of Subcutaneous Allergen Immunotherapy (SCIT) seen in numerous double-blind placebo controlled studies but recent evidence notes efficacy of sublingual immunotherapy (SLIT) which may be better tolerated than SCIT. This study assesses the efficacy and tolerability of both SCIT and SLIT in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have